Understanding the Prescribing and Adherence to sglt2i Medications by Patients With Ckd

Overview

About this study

The purpose of this study is to update the existing CVD Prevention tool for use with older adults with CKD and evaluate the implementation outcomes associated with incorporating the tool into practice.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients (18 years of age or older), with CKD or being evaluated for CKD, who present for a visit with a participating clinician.
  • Clinicians who see patients with or at risk of CKD are eligible to participate.

Exclusion Criteria:

  • Patients who do not speak English or lack the capacity to consent will not be included in this study. Additionally, patients with hyperthyroidism, pregnant patients, and those in which the nodule of interest has already been biopsied or who have received consultation with a thyroid nodule specialist will be excluded.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/25/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Michael Gionfriddo, Ph.D.

Open for enrollment

Contact information:

Michael Gionfriddo Ph.D.

(507) 266-1734

Gionfriddo.Michael@mayo.edu

More information

Publications

Publications are currently not available